Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07137338 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
A Phase 1 study, sponsored by Rocket Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07137338: Recruiting Phase 1 study, sponsored by Rocket Pharmaceuticals.
NCT07137338 is a Phase 1 study that is actively recruiting participants, run by Rocket Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07137338, a Phase 1 study, is actively recruiting participants, sponsored by Rocket Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Primary Outcome
Number of participants with Adverse Events following a single IV dose of RP-A701
Interventions
- GENETIC RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
What NCT07137338 shows while recruiting
NCT07137338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) is the first listed.
NCT07137338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07137338 about?
NCT07137338 is a clinical study titled "A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy". This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
What is the current status of trial NCT07137338?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-06. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07137338?
The interventions under investigation include: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) (GENETIC).
Who is sponsoring clinical trial NCT07137338?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07137338's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia